Adenocarcinoma: A unique cervical cancer

被引:211
作者
Gien, Lilian T. [2 ]
Beauchemin, Marie-Claude [1 ]
Thomas, Gillian [1 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook Hlth Sci Ctr, Div Gynecol Oncol, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
关键词
Adenocarcinoma; Cervix; Differences; Management; Prognosis; GYNECOLOGIC-ONCOLOGY-GROUP; SQUAMOUS-CELL CARCINOMA; ADENOSQUAMOUS HISTOLOGY PREDICTS; PELVIC RADIATION-THERAPY; UTERINE CERVIX; STAGE IB; RADICAL HYSTERECTOMY; CONCURRENT CHEMOTHERAPY; PROGNOSTIC-FACTORS; UNITED-STATES;
D O I
10.1016/j.ygyno.2009.09.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adenocarcinoma of the cervix constitutes only approximately 20% of all cervical carcinomas; therefore, specific Level 1 evidence to guide patient management is lacking. Most trials have included this histologic subtype but in insufficient numbers to do more than generate hypotheses from subset analyses. As a consequence, Our understanding of the natural history and optimal management of adenocarcinoma of the cervix is limited. The optimal management of adenocarcinoma of the cervix continues to be a subject of debate among practitioners as to whether or not it should be different from squamous cell carcinoma and what would constitute this management. The purpose of this review was to give an overview of the current knowledge on adenocarcinoma of the cervix and its differences from squamous cell carcinoma with regard to risk factors, prognosis, survival rates, patterns of recurrence, and response to treatment. This article will focus on possible specific therapeutic directions to explore in the management of locally advanced adenocarcinomas. (C) 2009 Published by Elsevier Inc.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 64 条
  • [1] Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix
    Alfsen, GC
    Reed, W
    Abeler, VM
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 282 - 289
  • [2] Alfsen GC, 2001, CANCER, V92, P2471, DOI 10.1002/1097-0142(20011101)92:9<2471::AID-CNCR1597>3.0.CO
  • [3] 2-K
  • [4] Prognostic factors in adenocarcinoma of the uterine cervix
    Baalbergen, A
    Ewing-Graham, PC
    Hop, WCJ
    Struijk, P
    Helmerhorst, TJM
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 262 - 267
  • [5] BEREK JS, 1985, OBSTET GYNECOL, V65, P46
  • [6] Incidence trends of adenocarcinoma of the cervix in 13 European countries
    Bray, F
    Carstensen, B
    Moller, H
    Zappa, M
    Zakelj, MP
    Lawrence, G
    Hakama, M
    Weiderpass, E
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (09) : 2191 - 2199
  • [7] Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors:: Implications for screening and prevention
    Castellsagué, X
    Díaz, M
    de Sanjosé, S
    Muñoz, N
    Herrero, R
    Franceschi, S
    Peeling, RW
    Ashley, R
    Smith, JS
    Snijders, PJF
    Meijer, CJLM
    Bosch, FX
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05): : 303 - 315
  • [8] Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan
    Chen, RJ
    Lin, YH
    Chen, CA
    Huang, SC
    Chow, SN
    Hsieh, CY
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 73 (02) : 184 - 190
  • [9] Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
    Curtin, JP
    Blessing, JA
    Webster, KD
    Rose, PG
    Mayer, AR
    Fowler, WC
    Malfetano, JH
    Alvarez, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1275 - 1278
  • [10] Cervical cancer: Effect of glandular cell type on prognosis, treatment, and survival
    Davy, MLJ
    Dodd, TJ
    Luke, CG
    Roder, DM
    [J]. OBSTETRICS AND GYNECOLOGY, 2003, 101 (01) : 38 - 45